Zenith Recruiting Metastatic Prostate Cancer Patients for New Clinical Trial
News
Zenith Epigenetics has started a Phase 1b clinical trial to assess the safety and tolerability of its orally administered BET inhibitor ZEN-3694 in combination with Xtandi (enzalutamide) in metastatic castration-resistant prostate ... Read more